On the public citation graph
One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines
0 signed · 95 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.289.24.3283openalex-snapshot
Myopericarditis Following Smallpox Vaccination Among Vaccinia-Naive US Military Personnel
inferredcites →https://doi.org/10.1007/s12199-010-0200-zopenalex-snapshot
Countermeasures and vaccination against terrorism using smallpox: pre-event and post-event smallpox vaccination and its contraindications
inferredcites →https://doi.org/10.1016/j.chom.2016.05.014openalex-snapshot
Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection
inferredcites →https://doi.org/10.1016/j.ijheh.2007.10.003openalex-snapshot
Determination of the appropriate quarantine period following smallpox exposure: An objective approach using the incubation period distribution
inferredcites →https://doi.org/10.1016/j.jacc.2003.11.053openalex-snapshot
Smallpox vaccination and myopericarditis: a clinical review
inferredcites →https://doi.org/10.1016/j.jacc.2004.05.004openalex-snapshot
Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination11The views expressed in this study are those of the authors and do not reflect the official policy or position of the U.S. government.
inferredcites →https://doi.org/10.1016/j.vaccine.2005.11.022openalex-snapshot
Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine
inferredcites →https://doi.org/10.1016/j.vaccine.2007.10.017openalex-snapshot
Clinical and immunologic responses to multiple doses of IMVAMUNE® (Modified Vaccinia Ankara) followed by Dryvax® challenge
inferredcites →https://doi.org/10.1016/j.vaccine.2009.05.095openalex-snapshot
Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain
inferredcites →https://doi.org/10.1016/j.vaccine.2009.11.030openalex-snapshot
A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE®
inferredcites →https://doi.org/10.1016/j.vaccine.2013.04.050openalex-snapshot
Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario
inferredcites →https://doi.org/10.1016/j.vaccine.2014.02.043openalex-snapshot
Phase II randomized, double-blinded comparison of a single high dose (5×108 TCID50) of modified vaccinia Ankara compared to a standard dose (1×108 TCID50) in healthy vaccinia-naïve individuals
inferredcites →https://doi.org/10.1016/j.vaccine.2014.08.022openalex-snapshot
Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis
inferredcites →https://doi.org/10.1016/j.vaccine.2015.06.075openalex-snapshot
Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects
inferredcites →https://doi.org/10.1016/j.vaccine.2020.01.058openalex-snapshot
A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS
inferredcites →https://doi.org/10.1016/j.virol.2007.02.041openalex-snapshot
Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate
inferredcites →https://doi.org/10.1016/j.virol.2007.04.010openalex-snapshot
DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge
inferredcites →https://doi.org/10.1056/nejm196911272812201openalex-snapshot
Complications of Smallpox Vaccination, 1968
inferredcites →https://doi.org/10.1056/nejmoa1817307openalex-snapshot
Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox
inferredcites →https://doi.org/10.1056/nejmoa2207323openalex-snapshot
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
inferredcites →https://doi.org/10.1073/pnas.0804985105openalex-snapshot
Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus
inferredcites →https://doi.org/10.1086/588197openalex-snapshot
Long‐Term Persistence of Mumps Antibody after Receipt of 2 Measles‐Mumps‐Rubella (MMR) Vaccinations and Antibody Response after a Third MMR Vaccination among a University Population
inferredcites →https://doi.org/10.1086/589862openalex-snapshot
Vaccines: Correlates of Vaccine‐Induced Immunity
inferredcites →https://doi.org/10.1093/aje/kwh269openalex-snapshot
Myopericarditis following Smallpox Vaccination
inferredcites →https://doi.org/10.1093/cid/cit684openalex-snapshot
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
inferredcites →https://doi.org/10.1093/cid/cit816openalex-snapshot
Executive Summary: 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
inferredcites →https://doi.org/10.1093/ije/17.3.643openalex-snapshot
The Transmission Potential of Monkeypox Virus in Human Populations
inferredcites →https://doi.org/10.1093/infdis/jis753openalex-snapshot
Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects
inferredcites →https://doi.org/10.1093/infdis/jit105openalex-snapshot
Safety and Immunogenicity of Modified Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial
inferredcites →https://doi.org/10.1093/ofid/ofv040openalex-snapshot
Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial
inferredcites →https://doi.org/10.1099/vir.0.010553-0openalex-snapshot
Evaluation of smallpox vaccines using variola neutralization
inferredcites →https://doi.org/10.1111/hiv.12424openalex-snapshot
B ritish HIV A ssociation Guidelines on the Use of Vaccines in HIV ‐Positive Adults 2015
inferredcites →https://doi.org/10.1111/jvh.13125openalex-snapshot
Persistence of HB sAg‐specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults
inferredcites →https://doi.org/10.1371/journal.pntd.0010141openalex-snapshot
The changing epidemiology of human monkeypox—A potential threat? A systematic review
inferredcites →https://doi.org/10.1371/journal.pone.0122653openalex-snapshot
Cardiac Safety of Modified Vaccinia Ankara for Vaccination against Smallpox in a Young, Healthy Study Population
inferredcites →https://doi.org/10.1371/journal.pone.0138348openalex-snapshot
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis
inferredcites →https://doi.org/10.1371/journal.pone.0157335openalex-snapshot
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects
inferredcites →https://doi.org/10.1371/journal.pone.0195897openalex-snapshot
Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial
inferredcites →https://doi.org/10.15585/mmwr.mm6510a2openalex-snapshot
Use of Vaccinia Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for Occupational Exposure to Orthopoxviruses — Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015
inferredcites →https://doi.org/10.15585/mmwr.mm6710a5openalex-snapshot
Emergence of Monkeypox — West and Central Africa, 1970–2017
inferredcites →https://doi.org/10.2807/1560-7917.es.2018.23.38.1800509openalex-snapshot
Two cases of monkeypox imported to the United Kingdom, September 2018
inferredcites →https://doi.org/10.2807/1560-7917.es.2022.27.24.2200448openalex-snapshot
Estimated incubation period for monkeypox cases confirmed in the Netherlands, May 2022
inferredcites →https://doi.org/10.3389/fimmu.2017.01590openalex-snapshot
Non-Neutralizing Antibodies Directed against HIV and Their Functions
inferredcites →https://doi.org/10.4161/hv.34393openalex-snapshot
The persistence of anti-HBs antibody and anamnestic response 20 years after primary vaccination with recombinant hepatitis B vaccine at infancy
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4572849openalex-extracted
Immunogenicity and Reactogenicity of Modified Vaccinia Ankara Pre-Exposure Vaccination Against Mpox According to Previous Smallpox Vaccine Exposure
inferred← citeshttps://doi.org/10.1002/jia2.70165openalex-snapshot
Durability of the Humoral Response to MPXV Infection
inferred← citeshttps://doi.org/10.1002/jmv.29134openalex-snapshot
Development of a novel serological assay for the detection of mpox infection in vaccinated populations
inferred← citeshttps://doi.org/10.1002/med.22085openalex-snapshot
An overview of the progress made in research into the Mpox virus
inferred← citeshttps://doi.org/10.1007/s10096-025-05242-1openalex-snapshot
From neglected to notoriety: a review of Mpox clinical features, virology, epidemiology, treatment and prevention strategies
inferred← citeshttps://doi.org/10.1016/bs.aivir.2026.03.001openalex-snapshot
Viral threats to pregnancy: Global health risks in the era of pandemics
inferred← citeshttps://doi.org/10.1016/j.biologicals.2026.101886openalex-snapshot
Alternative approaches to phase III clinical trials for vaccine efficacy and licensure: the role of real-world evidence – a meeting report
inferred← citeshttps://doi.org/10.1016/j.cell.2024.01.017openalex-snapshot
A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease
inferred← citeshttps://doi.org/10.1016/j.celrep.2025.116358openalex-snapshot
A single-dose nanoparticle vaccine protects against mpox in preclinical models
inferred← citeshttps://doi.org/10.1016/j.cmi.2024.03.038openalex-snapshot
History of smallpox vaccination and marked clinical expression of mpox among cases notified in France from May to July 2022
inferred← citeshttps://doi.org/10.1016/j.eclinm.2023.102420openalex-snapshot
Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study
inferred← citeshttps://doi.org/10.1016/j.jinf.2025.106602openalex-snapshot
Humoral and T-cell responses following MVA-BN booster vaccination against mpox virus clades Ib and IIb
inferred← citeshttps://doi.org/10.1016/j.jmb.2023.168173openalex-snapshot
Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases
inferred← citeshttps://doi.org/10.1016/j.meegid.2023.105477openalex-snapshot
Cross-reactive antibodies against monkeypox virus exist in the population immunized with vaccinia Tian Tan strain in China
inferred← citeshttps://doi.org/10.1016/j.vaccine.2024.05.017openalex-snapshot
Serologic responses to the MVA-based JYNNEOS mpox vaccine in a cohort of participants from the District of Columbia (D.C.)
inferred← citeshttps://doi.org/10.1016/j.vaccine.2024.126409openalex-snapshot
MVA-BN vaccine effectiveness: A systematic review of real-world evidence in outbreak settings
inferred← citeshttps://doi.org/10.1016/s1473-3099(25)00545-6openalex-snapshot
Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study
inferred← citeshttps://doi.org/10.1016/s1473-3099(26)00001-0openalex-snapshot
Immunogenicity and safety of MVA-BN vaccine administered 5 years after a two-dose primary series in DR Congo: a prospective cohort study
inferred← citeshttps://doi.org/10.1016/s1773-035x(24)00300-9openalex-snapshot
Vaccination contre le Mpox : état des lieux et perspectives
inferred← citeshttps://doi.org/10.1016/s1773-035x(25)76404-7openalex-snapshot
Intérêt et limites des corrélats immunologiques de protection
inferred← citeshttps://doi.org/10.1038/s41467-024-48180-wopenalex-snapshot
Predicting vaccine effectiveness for mpox
inferred← citeshttps://doi.org/10.1038/s41467-025-62594-0openalex-snapshot
Tiantan vaccinia virus-based vaccine with promising safety provides sustained protection against mpox in non-human primates
inferred← citeshttps://doi.org/10.1038/s41541-025-01289-5openalex-snapshot
Optimal deployment of limited vaccine supplies to control mpox outbreaks
inferred← citeshttps://doi.org/10.1080/14760584.2024.2397006openalex-snapshot
Vaccines against mpox: MVA-BN and LC16m8
inferred← citeshttps://doi.org/10.1080/14760584.2026.2708197openalex-snapshot
ACAM2000 vaccine safety and immunogenicity considerations for smallpox and mpox
inferred← citeshttps://doi.org/10.1080/17843286.2026.2706157openalex-snapshot
Mpox vaccination in Belgium: clinical guidance for implementation readiness
inferred← citeshttps://doi.org/10.1080/21645515.2024.2384189openalex-snapshot
Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccine
inferred← citeshttps://doi.org/10.1080/22221751.2023.2278900openalex-snapshot
Non-replicating vaccinia virus NTV as an effective next-generation smallpox and monkeypox vaccine: evidence from mouse and rhesus monkey models
inferred← citeshttps://doi.org/10.1093/infdis/jiag009openalex-snapshot
A Humoral Dilemma: Reassessing Monkeypox Virus Neutralizing Antibodies at More Than 2 Years From Mpox or Modified Vaccinia Ankara-Bavarian Nordic Vaccination
inferred← citeshttps://doi.org/10.1093/ofid/ofaf536openalex-snapshot
Antibody Responses are Sustained 2 Years Post-Mpox Infection but not Following Modified Vaccinia Ankara–Bavarian Nordic Vaccination
inferred← citeshttps://doi.org/10.1097/coh.0000000000001013openalex-snapshot
Pro/con: vaccination and waning immunity – presents contrasting perspectives on the durability of vaccine-induced protection and the potential need for booster strategies
inferred← citeshttps://doi.org/10.1101/2024.08.28.24312561openalex-snapshot
JYNNEOS vaccination induced short-lived neutralizing antibody responses to monkeypox virus in naïve individuals
inferred← citeshttps://doi.org/10.1101/2024.11.03.24316551openalex-snapshot
Optimal deployment of limited vaccine supplies to combat mpox
inferred← citeshttps://doi.org/10.1101/2025.10.31.25339252openalex-snapshot
A three-dose MVA-BN mpox vaccination series improves the quality of anti-monkeypox virus immunity
inferred← citeshttps://doi.org/10.1128/jvi.00253-25openalex-snapshot
The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response
inferred← citeshttps://doi.org/10.1186/s12916-025-04350-1openalex-snapshot
Gaps in the global health research landscape for mpox: an analysis of research activities and existing evidence
inferred← citeshttps://doi.org/10.21203/rs.3.rs-3817998/v1openalex-snapshot
Understanding the drivers of continued mpox transmission in the United States: a modeling study
inferred← citeshttps://doi.org/10.22207/jpam.16.spl1.22openalex-snapshot
Candidate Vaccines and Therapeutics against Monkeypox Infection
inferred← citeshttps://doi.org/10.2807/1560-7917.es.2024.29.38.2400575openalex-snapshot
Orthopoxvirus-specific antibodies wane to undetectable levels 1 year after MVA-BN vaccination of at-risk individuals, the Netherlands, 2022 to 2023
inferred← citeshttps://doi.org/10.3201/eid3102.241300openalex-snapshot
Short-Lived Neutralizing Antibody Responses to Monkeypox Virus in Smallpox Vaccine–Naive Persons after JYNNEOS Vaccination
inferred← citeshttps://doi.org/10.32388/gdwpcvopenalex-snapshot
A Historical to Future Perspective of Monkeypox Virus and Future Immunotherapeutics
inferred← citeshttps://doi.org/10.3390/microorganisms11112713openalex-snapshot
A Review of the Past, Present, and Future of the Monkeypox Virus: Challenges, Opportunities, and Lessons from COVID-19 for Global Health Security
inferred← citeshttps://doi.org/10.3390/v17121526openalex-snapshot
Mpox: Exploring Epidemiology, Disease Outcomes, and Preventative Vaccination Among People with HIV During the Ongoing Outbreaks
inferred← citeshttps://doi.org/10.3390/vaccines11091410openalex-snapshot
Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.3390/vaccines11111708openalex-snapshot
Systematic Review on the Efficacy, Effectiveness, Safety, and Immunogenicity of Monkeypox Vaccine
inferred← citeshttps://doi.org/10.3390/vaccines11121734openalex-snapshot
Knowledge, Attitudes, and Willingness of Healthcare Workers in Iraq’s Kurdistan Region to Vaccinate against Human Monkeypox: A Nationwide Cross-Sectional Study
inferred← citeshttps://doi.org/10.3390/vaccines13050520openalex-snapshot
Differences in Mpox and Vaccinia Immunity Induced by Non-Replicating and Replicating Vaccinia-Based Vaccines
inferred← citeshttps://doi.org/10.3390/vaccines13090930openalex-snapshot
Immune Response to MVA-BN Vaccination for Mpox: Current Evidence and Future Directions
inferred← citeshttps://doi.org/10.7554/elife.111935openalex-snapshot
A predictive systems vaccinology framework enables rational optimization of MVA-based vaccines
inferred← citeshttps://doi.org/10.7554/elife.111935.1openalex-snapshot
A predictive systems vaccinology framework enables rational optimization of MVA-based vaccines
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.